Therapeutic delivery of RNAi / Patrick Y. Lu.

Format:

Video

Author/Creator:

Lu, Patrick Y., author.

Series:

Henry Stewart talks

Language:

English

Subjects (All):

Interferon.

RNA interference.

Physical Description:

1 streaming video file (36 min., 41 sec.) : sound, color.

Place of Publication:

London : Henry Stewart Talks Ltd, 2007.

System Details:

video file

Summary:

Audio-visual presentation : RNAi therapeutics development ; RNAi cellular activity ; In vivo siRNA delivery is key ; Clinically viable siRNA deliveries ; Local delivery of siRNA ; Gene silencing in tumors ; Cancer target validation in vivo ; RNAi effects in mouse brain, joints, eyes and lungs ; siRNA therapeutics in primate models ; Challenges to siRNA systemic delivery ; Systemic delivery technology ; Targeted nanoparticle siRNA delivery ; Self assembled nanoparticle ; Integrin av-beta is a validated target ; Dual-targeted therapeutic approach ; Neovasculature targeting siRNA ; Multi-targeted anti-angiogenesis ; Efficient targeted systemic delivery ; Systemic siRNA delivery to eyes ; Systemic siRNA delivery for neuroblastoma treatment ; Tumor neovasculature inhibition ; siRNA/Atelocollagen anti-tumor efficacy ; Transferrin-mediated systemic delivery ; Antibody-mediated tumor targeting ; Targeted anti-HBV activity ; RNAi effect of chol-siRNA ; PEI-mediated siRNA lung targeting ; Clinicallyviable delivery is the key for successful siRNA therapeutics.

Contents:

Introduction

RNAi therapeutic development

RNAi cellular activity

In vivo siRNA delivery is the key

Clinically-viable siRNA deliveries

Intra-tumoral siRNA delivery

Gene silencing in tumor

Raf-1 siRNA inhibits tumor growth

siRNA-mediated validation in vivo

Cancer target validation

RNAi effect in mouse brain

RNAi effects in mouse CIA model

Ocular siRNA delivery subconjunctival

Ocular siRNA delivery: intravitreus

Intra-tracheal siRNA delivery

Primate study design

Relief from SCV-induced fever

Minimized lung damages

Protect monkey lung from infection

Challenges to siRNA systemic delivery

Systemic delivery technology

Targeted nanoparticle siRNA delivery

Self assembled nanoparticle

Integrin alfa-v-beta-3 is validated target

Dual-targeted therapeutic approach

Neovasculature targeting siRNA

Multi-targeted anti-angiogenesis

Systemic siRNA delivery to eyes

Efficient targeted systemic delivery

Neuroblastoma treatment

Tumor neovasculature inhibition

siRNA/atelocollagen anti-tumor efficacy

Transferrin-mediated systemic delivery

Antibody-mediated tumor targeting

Targeted anti-HBV activity

RNAi effect of chol-siRNA

PEI-mediated siRNA lung targeting

Conclusion: therapeutic delivery.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved April 12, 2024, from https://hstalks.com/bs/657/.